ReviewJournal of gynecologic oncology2015
Controversies in borderline ovarian tumors.
Review in Journal of gynecologic oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 89 citations in OpenAlex.
- Practical recommendations for fertility preservation in women by the FertiPROTEKT network. Part I: Indications for fertility preservation.Archives of gynecology and obstetrics · 2018Guideline
- Article
- Article
- A clinicopathological study of borderline ovarian tumors: insights from a tertiary care center in Saudi Arabia.BMC women's health · 2026Article
- The relationship between ovarian and colorectal cancers: a systematic review and meta-analysis.Korean journal of clinical oncology · 2025Article
- Impact of ovarian cystectomy on oncological and reproductive outcomes in borderline ovarian tumors: a retrospective study from a tertiary center.Journal of ovarian research · 2025Article
- Oncological safety of minimally invasive surgery in borderline ovarian tumor and ovarian cancer: a retrospective comparative study.Journal of gynecologic oncology · 2025Article
- Asian Society of Gynecologic Oncology (ASGO) 2024 Annual Meeting in Bali, Indonesia.Journal of gynecologic oncology · 2025Article
- Oncofertility outcomes after fertility-sparing surgery in infertile BOT patients: results of a large retrospective study on controlled ovarian stimulation.Frontiers in oncology · 2025Article
- An Analysis of Genetic Polymorphisms in 76 Genes Related to the Development of Ovarian Tumors of Different Aggressiveness.International journal of molecular sciences · 2024Article
- Usefulness of COL11A1 as a Prognostic Marker of Tumor Infiltration.Biomedicines · 2023Article
- Oncological and Reproductive Outcomes after Fertility-Sparing Surgery in Patients with Advanced-Stage Serous Borderline Ovarian Tumor: A Single-Center Retrospective Study.Journal of clinical medicine · 2023Article
- Evaluation of Borderline Ovarian Tumor Recurrence Rate after Surgery with or without Fertility-Sparing Approach: Results of a Retrospective Analysis.Healthcare (Basel, Switzerland) · 2023Article
- Pulmonary metastases of a borderline ovarian tumor with multiple cystic formations: a case report.Surgical case reports · 2023Article
- Bilateral Ovarian Serous Borderline Tumor with Non-Invasive Endometrial Implants.Case reports in obstetrics and gynecology · 2023Article
- Recurrence and 5-year survival rate in patients with borderline ovarian tumors and related factors in Kurdistan.European journal of translational myology · 2022Article
- Primary Fallopian Tube Carcinoma: An Extremely Rare Gynecological Cancer Misdiagnosed Intraoperatively as Benign Ovarian Neoplasm: A Case Report.Clinics and practice · 2022Article
- The challenging management of borderline ovarian tumors (BOTs) in women of childbearing age.Frontiers in surgery · 2022Review
- Status of Surgical Management of Borderline Ovarian Tumors in France: are Recommendations Being Followed? Multicentric French Study by the FRANCOGYN Group.Annals of surgical oncology · 2021Article
- Dysregulated Immunological Functionome and Dysfunctional Metabolic Pathway Recognized for the Pathogenesis of Borderline Ovarian Tumors by Integrative Polygenic Analytics.International journal of molecular sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Borderline ovarian tumors (BOTs) represent about 15% to 20% of all ovarian malignancies and differ from invasive ovarian cancers (IOCs) by many characters. Historically, standard management of BOT is peritoneal washing cytology, hysterectomy, bilateral salpingo-oophorectomy, omentectomy, complete peritoneal resection of macroscopic lesions; in case of mucinous BOTs, appendectomy should be performed. Because BOTs are often diagnosed at earlier stage, in younger age women and have better prognosis, higher survival rate than IOCs, fertility-sparing surgery is one of the option to preserve childbearing capacity. The study of such conservative surgery is being released, and still controversial. After surgery, pregnancy and ovarian induction followed by in vitro fertilization are also significant issues. In surgery, laparoscopic technique can be used by a gynecologic oncology surgeon. So far postoperative chemotherapy, radiotherapy and hormone therapy are not recommended. We will discuss controversial issues of BOTs on this review and present the outline of the management of BOTs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.